David Goldblatt

List of Publications by Year in Descending Order

250 papers	11,596 citations	58 h-index	98 g-index
289 ext. papers	14,018 ext. citations	8.2 avg, IF	6.39 L-index

#	Paper	IF	Citations
250	Corrected and Republished from: "A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Challenge".. *Infection and Immunity*, **2022**, 90, e0084618a	3.7	0
249	Opsonophagocytic Killing Assay to Measure Anti-Group A Streptococcus Antibody Functionality in Human Serum. *Methods in Molecular Biology*, **2022**, 2414, 373-386	1.4	
248	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.. *Nature Cancer*, **2022**,	15.4	5
247	Maintained partial protection against despite B-cell depletion in mice vaccinated with a pneumococcal glycoconjugate vaccine.. *Clinical and Translational Immunology*, **2022**, 11, e1366	6.8	1
246	SARS-CoV-2: from herd immunity to hybrid immunity.. *Nature Reviews Immunology*, **2022**,	36.5	5
245	Correlation of Fc Receptor Polymorphisms with Pneumococcal Antibodies in Vaccinated Kidney Transplant Recipients. *Vaccines*, **2022**, 10, 725	5.3	
244	Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera. *Vaccines*, **2022**, 10, 850	5.3	0
243	Towards a population-based threshold of protection for COVID-19 vaccines.. *Vaccine*, **2021**, 40, 306-306	4.1	10
242	Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines. *Journal of Infectious Diseases*, **2021**,	7	3
241	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. *Nature*, **2021**,	50.4	49
240	Cross-sectional prevalence of SARS-CoV-2 antibodies in healthcare workers in paediatric facilities in eight countries. *Journal of Hospital Infection*, **2021**, 110, 60-66	6.9	15
239	Generation of recombinant hyperimmune globulins from diverse B-cell repertoires. *Nature Biotechnology*, **2021**, 39, 989-999	44.5	2
238	Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial. *Lancet Infectious Diseases, The*, **2021**, 21, 688-696	25.5	3
237	Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial. *Lancet Infectious Diseases, The*, **2021**, 21, 834-846	25.5	11
236	Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. *New England Journal of Medicine*, **2021**, 384, 2202-2211	59.2	435
235	Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2. *Clinical Infectious Diseases*, **2021**,	11.6	11
234	Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 1104-1107	11.5	4

233	Preclinical Development of Virulence-attenuated Strains Able to Enhance Protective Immunity against Pneumococcal Infection. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 1037-1041	10.2	5
232	Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 604-613	10.2	9
231	Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial. *Lancet HIV,the*, **2021**, 8, e408-e419	7.8	2
230	Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers. *Pediatric Infectious Disease Journal*, **2021**, 40, 937-943	3.4	
229	SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK: A retrospective cohort study. *Lancet Regional Health - Europe, The*, **2021**, 6, 100127		8
228	Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*, **2021**, 39, 4423-4428	4.1	277
227	Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. *Lancet Haematology,the*, **2021**, 8, e542-e544	14.6	37
226	Antibodies to Seasonal Coronaviruses Rarely Cross-React With SARS-CoV-2: Findings From an African Birth Cohort. *Pediatric Infectious Disease Journal*, **2021**, 40, e516-e519	3.4	1
225	Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA. *Bioanalysis*, **2020**, 12, 1363-1375	2.1	7
224	Vaccine-Induced Th1-Type Response Protects against Invasive Group A Infection in the Absence of Opsonizing Antibodies. *MBio*, **2020**, 11,	7.8	10
223	Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. *Vaccine*, **2020**, 38, 3339-3350	4.1	12
222	A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults. *Pediatric Infectious Disease Journal*, **2020**, 39, 345-351	3.4	8
221	Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial. *Vaccine*, **2020**, 38, 399-410	4.1	14
220	Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment. *Clinical Infectious Diseases*, **2020**, 71, 1271-1280	11.6	2
219	Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing. *Vaccine*, **2020**, 38, 7834-7841	4.1	
218	Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. *Journal of Clinical Virology*, **2020**, 130, 104572	14.5	49
217	Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. *Lancet Infectious Diseases, The*, **2020**, 20, 1426-1436	25.5	3
216	The Influence of B Cell Depletion Therapy on Naturally Acquired Immunity to. *Frontiers in Immunology*, **2020**, 11, 611661	8.4	2

215	An Opsonophagocytic Killing Assay for the Evaluation of Group A Streptococcus Vaccine Antisera. *Methods in Molecular Biology*, **2020**, 2136, 323-335	1.4	3
214	Serocorrelates of protection against infant group B streptococcus disease. *Lancet Infectious Diseases, The*, **2019**, 19, e162-e171	25.5	30
213	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. *Vaccine*, **2019**, 37, 3190-3198	4.1	17
212	An Experimental Group A Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model. *MBio*, **2019**, 10,	7.8	29
211	Comparison between a new multiplex electrochemiluminescence assay and the WHO reference enzyme-linked immunosorbent assay to measure serum antibodies against pneumococcal serotype-specific polysaccharides. *Vaccine*, **2019**, 37, 2208-2215	4.1	4
210	Health-Related Quality of Life and Emotional Health in X-Linked Carriers of Chronic Granulomatous Disease in the United Kingdom. *Journal of Clinical Immunology*, **2019**, 39, 195-199	5.7	5
209	The duopoly of ten-valent and 13-valent pneumococcal conjugate vaccines: do they differ?. *Lancet Infectious Diseases, The*, **2019**, 19, 453-454	25.5	3
208	Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines - AuthorsPreply. *Lancet Infectious Diseases, The*, **2019**, 19, 693-694	25.5	
207	Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial. *Lancet Infectious Diseases, The*, **2019**, 19, 156-164	25.5	8
206	A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Challenge. *Infection and Immunity*, **2019**, 87,	3.7	13
205	Effect of Maternally Derived Anti-protein and Anticapsular IgG Antibodies on the Rate of Acquisition of Nasopharyngeal Carriage of Pneumococcus in Newborns. *Clinical Infectious Diseases*, **2018**, 66, 121-130	11.6	6
204	A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. *Journal of Rheumatology*, **2018**, 45, 733-744	4.1	50
203	Neonatal Immunization: Rationale, Current State, and Future Prospects. *Frontiers in Immunology*, **2018**, 9, 532	8.4	29
202	Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I. *Vaccine*, **2018**, 36, 4944-4951	4.1	4
201	Development of an opsonophagocytic killing assay for group a streptococcus. *Vaccine*, **2018**, 36, 3756-3763	4.1	15
200	Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial. *Lancet Infectious Diseases, The*, **2018**, 18, 171-179	25.5	70
199	Outpacing the pneumococcus: Antibody dynamics in the first few days following pneumococcal capsular antigen stimulation. *Scientific Reports*, **2018**, 8, 15376	4.9	2
198	Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. *Biologicals*, **2018**, 56, 29-38	1.8	13

197	Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam. *Human Vaccines and Immunotherapeutics*, **2018**, 14, 1939-1947	4.4	12
196	Reassessing the 1 + 1 pneumococcal conjugate vaccine schedule - AuthorsPreply. *Lancet Infectious Diseases, The*, **2018**, 18, 382-383	25.5	1
195	Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae. *Vaccine*, **2018**, 36, 4255-4264	4.1	5
194	Assignment of Opsonic Values to Pneumococcal Reference Serum 007sp for Use in Opsonophagocytic Assays for 13 Serotypes. *Vaccine Journal*, **2017**, 24,		19
193	Raised Serum IL-8 Levels Are Associated with Excessive Fatigue in Female Carriers of X-Linked Chronic Granulomatous Disease in the UK. *Journal of Clinical Immunology*, **2017**, 37, 279-281	5.7	5
192	Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy. *Pediatric Infectious Disease Journal*, **2017**, 36, 1186-1192	3.4	24
191	Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 628-630.e6	11.5	36
190	An Uncommon Site of Colonization Leading to Recurrent Pneumococcal Disease. *Open Forum Infectious Diseases*, **2017**, 4, ofw257	1	4
189	The indirect effect of pneumococcal conjugate vaccine. *The Lancet Global Health*, **2017**, 5, e6-e7	13.6	2
188	A longitudinal study of the infant nasopharyngeal microbiota: The effects of age, illness and antibiotic use in a cohort of South East Asian children. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005975	4.8	31
187	Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics. *MAbs*, **2017**, 9, 1282-1296	6.6	29
186	Assignment of Weight-Based Antibody Units for Four Additional Serotypes to a Human Antipneumococcal Standard Reference Serum, 007sp. *Vaccine Journal*, **2017**, 24,		3
185	Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage. *Vaccine*, **2017**, 35, 4652-4657	4.1	17
184	Natural IgM antibodies in the immune defence against neoehrlichiosis. *Infectious Diseases*, **2017**, 49, 809-816	3.1	4
183	Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. *Vaccine*, **2017**, 35, 5186-5193	4.1	10
182	Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial. *Vaccine*, **2017**, 35, 7181-7186	4.1	20
181	Naturally Acquired Human Immunity to Pneumococcus Is Dependent on Antibody to Protein Antigens. *PLoS Pathogens*, **2017**, 13, e1006137	7.6	57
180	Genome-wide identification of lineage and locus specific variation associated with pneumococcal carriage duration. *ELife*, **2017**, 6,	8.9	50

179	Association of Pneumococcal Protein Antigen Serology With Age and Antigenic Profile of Colonizing Isolates. *Journal of Infectious Diseases*, **2017**, 215, 713-722	7	17
178	Association of Low B Cell Count and IgG Levels With Infection, and Poor Vaccine Response With All-Cause Mortality in an Immunosuppressed Vasculitis Population. *Arthritis Care and Research*, **2016**, 68, 853-60	4.7	13
177	Maternal and neonatal pneumococcal vaccination - where are we now?. *Expert Review of Vaccines*, **2016**, 15, 1305-17	5.2	12
176	Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom Macroglobulinemia. *Vaccine Journal*, **2016**, 23, 379-85		16
175	The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. *Pediatric Infectious Disease Journal*, **2016**, 35, 787-93	3.4	13
174	Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study. *The Lancet Global Health*, **2016**, 4, e185-94	13.6	34
173	B-cell development and pneumococcal immunity in vertically acquired HIV infection. *Aids*, **2016**, 30, 1867-76	3.5	2
172	Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. *Pediatrics*, **2016**, 138,	7.4	18
171	Climate induces seasonality in pneumococcal transmission. *Scientific Reports*, **2015**, 5, 11344	4.9	31
170	Genomics Reveals the Worldwide Distribution of Multidrug-Resistant Serotype 6E Pneumococci. *Journal of Clinical Microbiology*, **2015**, 53, 2271-85	9.7	21
169	Antibody Response is More Likely to Pneumococcal Proteins Than to Polysaccharide After HIV-associated Invasive Pneumococcal Disease. *Journal of Infectious Diseases*, **2015**, 212, 1093-9	7	4
168	Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. *Clinical Infectious Diseases*, **2015**, 61, 1637-44	11.6	310
167	Assignment of Weight-Based Antibody Units for Seven Additional Serotypes to a Human Pneumococcal Standard Reference Serum, 007sp. *Vaccine Journal*, **2015**, 22, 1154-9		8
166	Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets. *Infection and Immunity*, **2015**, 83, 2889-96	3.7	5
165	Persistence of IgG antibody following routine infant immunization with the 7-valent pneumococcal conjugate vaccine. *Pediatric Infectious Disease Journal*, **2015**, 34, e138-42	3.4	3
164	The influence of paediatric HIV infection on circulating B cell subsets and CXCR5(+) T helper cells. *Clinical and Experimental Immunology*, **2015**, 181, 110-7	6.2	17
163	The Efficacy and Duration of Protection of Pneumococcal Conjugate Vaccines Against Nasopharyngeal Carriage: A Meta-regression Model. *Pediatric Infectious Disease Journal*, **2015**, 34, 858-64	3.4	32
162	Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia. *Emerging Infectious Diseases*, **2015**, 21, 2080-3	10.2	13

161	The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries. *PLoS Medicine*, **2015**, 12, e1001839	11.6	42
160	Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies. *Vaccine Journal*, **2015**, 22, 404-12		7
159	Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch. *Vaccine*, **2015**, 33, 6675-83	4.1	14
158	Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule. *Vaccine*, **2015**, 33, 648-55	4.1	13
157	Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants. *PLoS ONE*, **2015**, 10, e0144739	3.7	27
156	Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: a randomized phase I clinical trial. *Vaccine*, **2014**, 32, 5266-70	4.1	17
155	Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. *Lancet Infectious Diseases, The*, **2014**, 14, 839-46	25.5	330
154	Dense genomic sampling identifies highways of pneumococcal recombination. *Nature Genetics*, **2014**, 46, 305-309	36.3	269
153	Recent advances in chronic granulomatous disease. *Journal of Infection*, **2014**, 69 Suppl 1, S32-5	18.9	29
152	Safety, tolerability, and biomarkers of the treatment of mice with aerosolized Toll-like receptor ligands. *Frontiers in Pharmacology*, **2014**, 5, 8	5.6	17
151	Comprehensive identification of single nucleotide polymorphisms associated with beta-lactam resistance within pneumococcal mosaic genes. *PLoS Genetics*, **2014**, 10, e1004547	6	132
150	Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S161-71	3.4	71
149	Why do we need a systematic review of pneumococcal conjugate vaccine dosing schedules?. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S107-8	3.4	4
148	Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. *Aids*, **2014**, 28, 2033-43	3.5	21
147	Methods for a systematic review of pneumococcal conjugate vaccine dosing schedules. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S182-7	3.4	10
146	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S140-51	3.4	75
145	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S119-29	3.4	41
144	Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S172-81	3.4	58

143	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S152-60	3.4	72
142	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S109-18	3.4	76
141	The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S130-9	3.4	23
140	Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. *PLoS ONE*, **2014**, 9, e85459	3.7	31
139	Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. *Journal of Clinical Immunology*, **2013**, 33, 8-13	5.7	56
138	Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 1150-5	11.5	81
137	Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. *Vaccine*, **2013**, 31, 1453-7	4.1	30
136	Clinical manifestations of disease in X-linked carriers of chronic granulomatous disease. *Journal of Clinical Immunology*, **2013**, 33, 1276-84	5.7	55
135	Nonsense in Public Places: Songs of Black Vocal Rhythm and Blues or Doo-Wop. *Journal of Aesthetics and Art Criticism*, **2013**, 71, 101-110	0.3	
134	Umhlaba 1913–2013. *Social Dynamics*, **2013**, 39, 327-352	0.2	
133	Infection risk in ANCA-associated vasculitis. *Presse Medicale*, **2013**, 42, 665-666	2.2	
132	Colonisation endpoints in Streptococcus pneumoniae vaccine trials. *Vaccine*, **2013**, 32, 153-8	4.1	39
131	Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose. *Vaccine*, **2013**, 31, 5834-42	4.1	4
130	Design questions for Streptococcus pneumoniae vaccine trials with a colonisation endpoint. *Vaccine*, **2013**, 32, 159-64	4.1	14
129	Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 855-64	10.2	110
128	Cognitive ability in children with chronic granulomatous disease: a comparison of those managed conservatively with those who have undergone hematopoietic stem cell transplant. *Neuropediatrics*, **2013**, 44, 230-2	1.6	9
127	The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination. *Proceedings of the Royal Society B: Biological Sciences*, **2013**, 280, 20131939	4.4	24
126	Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study. *Clinical Microbiology and Infection*, **2013**, 19, E551-8	9.5	42

125	High rates of pneumonia in children under two years of age in a South East Asian refugee population. *PLoS ONE*, **2013**, 8, e54026	3.7	25
124	Field evaluation of culture plus latex sweep serotyping for detection of multiple pneumococcal serotype colonisation in infants and young children. *PLoS ONE*, **2013**, 8, e67933	3.7	13
123	Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. *PLoS ONE*, **2013**, 8, e74906	3.7	49
122	Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. *PLoS ONE*, **2013**, 8, e51460	3.7	25
121	The fundamental link between pneumococcal carriage and disease. *Expert Review of Vaccines*, **2012**, 11, 841-55	5.2	408
120	Early-life and contemporaneous nutritional and environmental predictors of antibody response to vaccination in young Gambian adults. *Vaccine*, **2012**, 30, 4842-8	4.1	9
119	Assessment of Streptococcus pneumoniae pilus islet-1 prevalence in carried and transmitted isolates from mother-infant pairs on the Thailand-Burma border. *Clinical Microbiology and Infection*, **2012**, 18, 970-5	9.5	15
118	A high burden of respiratory syncytial virus associated pneumonia in children less than two years of age in a South East Asian refugee population. *PLoS ONE*, **2012**, 7, e50100	3.7	9
117	RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. *Infection and Immunity*, **2012**, 80, 451-60	3.7	36
116	Emotional and behavioural difficulties in chronic granulomatous disease. *Archives of Disease in Childhood*, **2012**, 97, 87	2.2	6
115	Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom. *Pediatric Infectious Disease Journal*, **2012**, 31, 616-22	3.4	30
114	A longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. *PLoS ONE*, **2012**, 7, e38271	3.7	89
113	The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. *Vaccine*, **2011**, 29, 2999-3007	4.1	30
112	Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. *Journal of Clinical Microbiology*, **2011**, 49, 1784-9	9.7	118
111	Establishment of a new human pneumococcal standard reference serum, 007sp. *Vaccine Journal*, **2011**, 18, 1728-36		77
110	Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. *Vaccine Journal*, **2011**, 18, 367-72		19
109	Detection of respiratory viruses by PCR assay of nasopharyngeal swabs stored in skim milk-tryptone-glucose-glycerol transport medium. *Journal of Clinical Microbiology*, **2011**, 49, 2311-3	9.7	11
108	Comparison of a new multiplex binding assay versus the enzyme-linked immunosorbent assay for measurement of serotype-specific pneumococcal capsular polysaccharide IgG. *Vaccine Journal*, **2011**, 18, 1744-51		26

107	Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. *Vaccine Journal*, **2011**, 18, 135-42		53
106	Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. *Clinical Infectious Diseases*, **2011**, 53, 663-70	11.6	44
105	The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. *Vaccine*, **2010**, 28, 4763-70	4.1	33
104	Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. *Vaccine*, **2010**, 28, 6915-22	4.1	15
103	Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. *Pediatric Infectious Disease Journal*, **2010**, 29, 401-5	3.4	57
102	Dendritic cell anergy results from endotoxemia in severe malnutrition. *Journal of Immunology*, **2009** , 183, 2818-26	5.3	55
101	Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. *Journal of Immunology*, **2009**, 183, 5622-9	5.3	102
100	CD4 counts decline despite nutritional recovery in HIV-infected Zambian children with severe malnutrition. *Pediatrics*, **2009**, 123, e347-51	7.4	26
99	Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae. *European Journal of Immunology*, **2009**, 39, 1527-35	6.1	7
98	The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. *Clinical Infectious Diseases*, **2009**, 49, 1318-25	11.6	125
97	Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. *Clinical and Experimental Immunology*, **2008**, 151, 51-60	6.2	55
96	Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. *Clinical and Experimental Immunology*, **2008**, 152, 211-8	6.2	173
95	Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous and allogeneic T cells. *Immunology*, **2008**, 125, 469-79	7.8	5
94	Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia. *Vaccine*, **2008**, 26, 3719-26	4.1	38
93	Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. *Vaccine*, **2008**, 26, 4434-45	4.1	107
92	Bacteria, polysaccharides, vaccines and boosting: measuring and maintaining population immunity. *Archives of Disease in Childhood*, **2008**, 93, 646-7	2.2	8
91	Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. *Clinical and Experimental Immunology*, **2007**, 148, 79-84	6.2	105
90	Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. *Vaccine Journal*, **2007**, 14, 397-403		14

89	Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. *Vaccine Journal*, **2007**, 14, 1328-33		26
88	Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. *Vaccine Journal*, **2007**, 14, 1362-9		38
87	Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. *Lancet, The*, **2007**, 369, 1440-1451	40	216
86	WHO guidelines for treatment of severe pneumonia AuthorsReply. *Lancet, The*, **2007**, 370, 385-386	40	0
85	Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. *Lancet Infectious Diseases, The*, **2007**, 7, 597-606	25.5	173
84	Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. *Vaccine Journal*, **2006**, 13, 356-60		105
83	Pneumococcal polysaccharides interact with human dendritic cells. *Infection and Immunity*, **2006**, 74, 1890-5	3.7	30
82	Lack of association between the nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in HIV-1-infected South African children. *Journal of Infectious Diseases*, **2006**, 194, 385-90	7	66
81	Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. *Journal of Infectious Diseases*, **2006**, 194, 1745-52	7	128
80	Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. *Vaccine Journal*, **2006**, 13, 165-9		165
79	Reply to Bogaert et al.. *Journal of Infectious Diseases*, **2006**, 194, 1618-1619	7	4
78	Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies. *Infection and Immunity*, **2006**, 74, 1025-31	3.7	13
77	Pneumococcal vaccination in developing countries. *Lancet, The*, **2006**, 367, 1880-2	40	142
76	Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. *Pediatric Infectious Disease Journal*, **2006**, 25, 312-9	3.4	130
75	Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan. *Tropical Medicine and International Health*, **2006**, 11, 1529-41	2.3	38
74	Probable mother to infant transmission of Pneumocystis jiroveci from an HIV-infected woman to her HIV-uninfected infant. *Aids*, **2005**, 19, 1548-9	3.5	23
73	Chronic granulomatous disease: from genetic defect to clinical presentation. *Advances in Experimental Medicine and Biology*, **2005**, 568, 67-87	3.6	28
72	Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. *Journal of Infectious Diseases*, **2005**, 192, 387-93	7	189

71	Hib IgG persistence following early booster dose. *Archives of Disease in Childhood*, **2005**, 90, 329	2.2	
70	Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. *Archives of Disease in Childhood: Fetal and Neonatal Edition*, **2004**, 89, F269-71	4.7	22
69	Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. *Vaccine Journal*, **2004**, 11, 1100-4		44
68	Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. *Infection and Immunity*, **2004**, 72, 5383-91	3.7	74
67	Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. *Vaccine Journal*, **2003**, 10, 1019-24		52
66	The nature of colitis in chronic granulomatous disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2003**, 36, 623-31	2.8	60
65	Humoral immunity in children with biliary atresia splenic malformation syndrome. *European Journal of Pediatrics*, **2003**, 162, 539-540	4.1	9
64	Conjugate Hib vaccines. *Lancet, The*, **2003**, 361, 360-1	40	31
63	Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. *Lancet, The*, **2003**, 362, 449-50	40	44
62	Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. *Vaccine*, **2003**, 21, 3265-72	4.1	283
61	Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. *Vaccine Journal*, **2003**, 10, 514-9		251
60	Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. *Infection and Immunity*, **2003**, 71, 5549-55	3.7	84
59	Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). *Journal of Leukocyte Biology*, **2003**, 73, 591-9	6.5	117
58	Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. *Clinical and Experimental Immunology*, **2002**, 128, 118-23	6.2	156
57	Increased expression of interleukin-13 but not interleukin-4 in CD4+ cells from patients with the hyper-IgE syndrome. *Clinical and Experimental Immunology*, **2002**, 128, 532-7	6.2	18
56	A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma. *Vox Sanguinis*, **2002**, 83, 17-22	3.1	17
55	Prenatal diagnosis in two families with autosomal, p47(phox)-deficient chronic granulomatous disease due to a novel point mutation in NCF1. *Prenatal Diagnosis*, **2002**, 22, 235-40	3.2	18
54	Current treatment options for chronic granulomatous disease. *Expert Opinion on Pharmacotherapy*, **2002**, 3, 857-63	4	24

53	Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. *Journal of Infectious Diseases*, **2002**, 185, 397-400	7	54
52	Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. *Infection and Immunity*, **2002**, 70, 4946-54	3.7	80
51	Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. *Journal of Infectious Diseases*, **2002**, 186, 1353-7	7	99
50	Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. *Pediatric Infectious Disease Journal*, **2002**, 21, 940-7	3.4	28
49	Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. *Vaccine*, **2002**, 20, 2592-6	4.1	37
48	X-linked lymphoproliferative disease: three atypical cases. *Clinical and Experimental Immunology*, **2001**, 126, 126-30	6.2	45
47	Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. *Infection and Immunity*, **2001**, 69, 1568-73	3.7	281
46	Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. *Journal of Infectious Diseases*, **2001**, 184, 1617-20	7	74
45	Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. *Journal of Infectious Diseases*, **2001**, 184, 377-80	7	65
44	Colitis in chronic granulomatous disease. *Archives of Disease in Childhood*, **2001**, 84, 147-51	2.2	106
43	Hematopoietic-cell transplantation for chronic granulomatous disease. *New England Journal of Medicine*, **2001**, 345, 377-8	59.2	4
42	Immune response and host-pathogen interactions. *Methods in Molecular Medicine*, **2001**, 66, 23-39		1
41	Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. *Journal of Infectious Diseases*, **2001**, 183, 160-3	7	200
40	Clinical relevance of lower Hib response in DTPa-based combination vaccines. *Vaccine*, **2001**, 19, 2280-5	4.1	49
39	Immunogenetic analysis of the immune response to pneumococcal polysaccharide. *European Journal of Immunology*, **2000**, 30, 1214-23	6.1	68
38	Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression. *European Journal of Immunology*, **2000**, 30, 1691-7	6.1	62
37	Follow up of patients with chronic granulomatous disease diagnosed since 1990. *Clinical and Experimental Immunology*, **2000**, 120, 351-5	6.2	72
36	Preparation of human-mouse heterohybridomas against an immunising antigen. *Journal of Immunological Methods*, **2000**, 246, 187-202	2.5	18

35	An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. *Journal of Clinical Microbiology*, **2000**, 38, 2043-50	9.7	65
34	Immunogenetic analysis of the immune response to pneumococcal polysaccharide **2000**, 30, 1214		1
33	An Analytical Model Applied to a Multicenter Pneumococcal Enzyme-Linked Immunosorbent Assay Study. *Journal of Clinical Microbiology*, **2000**, 38, 2043-2050	9.7	7
32	The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. *Journal of Infectious Diseases*, **1999**, 180, 538-41	7	78
31	Pericardial effusions in two boys with chronic granulomatous disease. *Pediatric Radiology*, **1999**, 29, 820-2	2.8	7
30	Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. *Vaccine*, **1999**, 18, 641-6	4.1	69
29	Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. *Lancet, The*, **1999**, 354, 2063-8	40	186
28	Chorioretinal lesions in patients and carriers of chronic granulomatous disease. *Journal of Pediatrics* , **1999**, 134, 780-3	3.6	75
27	A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. *Vaccine Journal*, **1999**, 6, 581-6		59
26	Antibody response to outer membrane proteins of Moraxella catarrhalis in children with otitis media. *Pediatric Infectious Disease Journal*, **1999**, 18, 982-8	3.4	28
25	Hospital admissions in children due to pneumococcal pneumonia in England. *Journal of Infection*, **1998**, 37, 54-8	18.9	34
24	Measles vaccination and inflammatory bowel disease. *Lancet, The*, **1998**, 351, 755-6	40	9
23	Autism, inflammatory bowel disease, and MMR vaccine. *Lancet, The*, **1998**, 351, 1355-6; author reply 1356	40	2
22	Recent developments in bacterial conjugate vaccines. *Journal of Medical Microbiology*, **1998**, 47, 563-7	3.2	48
21	Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. *Journal of Infectious Diseases*, **1998**, 177, 1112-5	7	193
20	Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). *Journal of Immunological Methods*, **1997**, 205, 67-72	2.5	35
19	Characterisation of an outer membrane protein of Moraxella catarrhalis. *FEMS Immunology and Medical Microbiology*, **1997**, 19, 231-6		15
18	Transfusion associated graft-versus-host disease in DiGeorge syndrome. Index case report with survey of screening procedures and use of irradiated blood components. *Cardiology in the Young*, **1996**, 6, 222-227	1	8

17	Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses. *Immunology*, **1996**, 88, 169-73	7.8	33
16	Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease. *Archives of Disease in Childhood*, **1996**, 75, 159-61	2.2	21
15	Interchangeability of conjugated Haemophilus influenzae type b vaccines during primary immunisation of infants. *BMJ: British Medical Journal*, **1996**, 312, 817-8		12
14	Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. *Pediatric Infectious Disease Journal*, **1996**, 15, 1097-101	3.4	33
13	Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. *Pediatric Infectious Disease Journal*, **1995**, 14, 129-35	3.4	35
12	The role of pH in modified ELISA procedures used for the estimation of functional antibody affinity. *Journal of Immunological Methods*, **1993**, 166, 281-5	2.5	32
11	Role of cell wall polysaccharide in the assessment of IgG antibodies to the capsular polysaccharides of Streptococcus pneumoniae in childhood. *Journal of Infectious Diseases*, **1992**, 166, 632-4	7	33
10	Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood. *Journal of Infectious Diseases*, **1990**, 162, 1128-35	7	59
9	An enzyme-linked immunosorbent assay for the determination of human IgG subclass antibodies directed against Branhamella catarrhalis. *Journal of Immunological Methods*, **1990**, 128, 219-25	2.5	19
8	The Immunobiology of Polysaccharide and Conjugate Vaccines67-82		5
7	Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam: a dynamic transmission model		1
6	Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2		2
5	Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs		2
4	Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2		2
3	Extremely high SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK		6
2	A Population-Based Threshold of Protection for COVID-19 Vaccines		4
1	Correlates of protection against SARS - CoV -2 infection and COVID-19 disease. *Immunological Reviews*,	11.3	6